Comparison of Cardiac Index Measurement Using Right Ventricular Pressure Curve Analysis and Thermodilution Via a Swan-Ganz IQ™ Catheter.
MICAP
1 other identifier
observational
43
1 country
2
Brief Summary
The pulmonary artery catheter (Swan-Ganz) is a standard tool in intensive care for measuring and monitoring cardiac index by thermodilution. The Swan-Ganz IQ™ model also allows continuous estimation of cardiac index through analysis of the right ventricular pressure wave, which could be useful for rapidly assessing changes in cardiac output during volume expansion response tests. However, the concordance between this continuous method and thermodilution remains poorly studied in real clinical conditions and may vary depending on certain clinical situations. This study therefore aims to compare the cardiac index measured by thermodilution with that estimated by right ventricular pressure waveform analysis based on data collected in clinical practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2026
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 1, 2026
CompletedFirst Posted
Study publicly available on registry
June 4, 2026
CompletedStudy Start
First participant enrolled
June 10, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 10, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 10, 2028
June 4, 2026
May 1, 2026
2 years
June 1, 2026
June 1, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Evaluate the concordance between cardiac index values provided according to right ventricular pressure waveform and those measured by thermodilution in patients with septic shock who are monitored by a pulmonary.
1 day
Secondary Outcomes (6)
Evaluate the concordance between the continuous cardiac index estimated by the Swan-Ganz IQ™ catheter and the cardiac index measured by thermodilution in patients receiving vasopressor therapy, compared to patients not receiving vasopressor therapy.
1 day
Assess whether the agreement between cardiac index measured by thermodilution and that estimated by Swan-Ganz IQ™ varies across different hemodynamic profiles.
1 day
Assess the concordance between variations in cardiac index measured by thermodilution and those in continuous cardiac index estimated by right ventricular pressure wave analysis, before and after volume expansion performed as part of treatment.
1 day
Assess the consistency of changes in cardiac output before and after volume expansion, depending on the use of vasopressors.
1 day
Assess the agreement between changes in cardiac output measured by thermodilution and those estimated continuously by analysis of the right ventricular pressure wave, before and after a change in the dose of norepinephrine.
1 day
- +1 more secondary outcomes
Interventions
The pulmonary artery catheter (or Swan-Ganz catheter) is a gold-standard tool for measuring and monitoring cardiac index in the intensive care unit. It enables measurement of cardiac index via thermodilution, which is considered the gold standard method. The Swan-Ganz IQ™ model also provides continuous measurement of cardiac index through analysis of the right ventricular pressure wave.
Eligibility Criteria
Patients hospitalized in medical ICU (of Bicêtre and Angers) with pulmonary arterial catheter (PAC) place as part of routine clinical care.
You may qualify if:
- Age ≥ 18 years
- Hospitalization in intensive care
- Presence of a Swan-Ganz IQ™ pulmonary artery catheter placed as part of treatment
- Thermodilution performed by the clinician in charge as part of treatment
You may not qualify if:
- Pregnancy
- Legal protective measures (guardianship, conservatorship, and deprivation of liberty by court/administrative decision)
- Refusal of participation by the patient's relatives or the patient themselves.
- Cardiac output measurements by thermodilution or continuous cardiac output analysis that cannot be used.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Pierre ASFAR
Angers, 49100, France
Xavier MONNET
Paris, 94000, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Xavier MONNET, PhD
Assistance Publique - Hôpitaux de Paris
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 1, 2026
First Posted
June 4, 2026
Study Start
June 10, 2026
Primary Completion (Estimated)
June 10, 2028
Study Completion (Estimated)
June 10, 2028
Last Updated
June 4, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share